 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Research > Celsion Corporation
 |
Celsion Corporation |
 |
 |
 |
PROFILE |
 |
Celsion's microwave therapy zaps tumors. Using technology originally developed at MIT for the US Department of Defense, Celsion is working on treatments for breast cancer and benign prostatic hyperplasia. In the procedure, which the company touts as an alternative to surgery, chemotherapy, or drugs, relatively low heat (less than 120 degrees Fahrenheit) is focused on a tumor without burning surrounding tissue. The company is also collaborating with Memorial Sloan-Kettering Cancer Center and licensing technology from Duke University. Celsion plans to develop microwave treatments for prostate and other cancers, as well as for inflammatory, infectious, and genetic diseases.
COMPETITION |
 |
EDAP TMS S.A. (EDAPY)
Urologix, Inc. (ULGX)
VidaMed, Inc. (VIDA)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: September
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: 0.0%
Employees: 28
Revenue per employee: $3,571.43
KEY PEOPLE |
 |
Spencer J. Volk
CEO
Anthony P. Deasey
CFO
CONTACT INFO |
 |
10220-I Old Columbia Rd.
Columbia, MD 21046
US
Phone: 410-290-5390
Fax: 410-290-5394
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |